Smartphone App for Asthma Self-care: Assessment of Outcomes (Asthma Progession and Costs)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Ministry of Science and Technology, Taiwan
- Enrollment
- 140
- Locations
- 1
- Primary Endpoint
- All participants were assessed for the Asthma Control Test (ACT) change using ACT questionnaire from quality metric incorporated
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this clinical trial is to investigate whether a smartphone app based on the Global Initiative for Asthma (GINA) guidelines can improve asthma control and quality of life, and decrease asthma-related costs in children. The main question it to answer whether this app can improve asthma control, increase the quality of life, and decrease asthma-related costs.
Participants in the intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits, while the control group received reminder calls. Researchers will compare with the control group to see if the intervention receives more asthma control improvement.
Investigators
I-Jen, Wang
Clinical Professor
Taipei Hospital, Ministry of Health and Welfare
Eligibility Criteria
Inclusion Criteria
- •aged between 3 and 18 years;
- •who had access to the smartphone app;
- •with asthma treatment steps 2-4, requiring regular treatment with controller medication (for at least 6 months over the past year) according to the GINA guidelines;
- •who had at least two clinic or emergency department visits related to asthma in the previous year.
Exclusion Criteria
- •Children who had comorbidities, or other major medical problems, and who did not have a smartphone or whose caregivers did not have a smartphone were excluded from the study.
Outcomes
Primary Outcomes
All participants were assessed for the Asthma Control Test (ACT) change using ACT questionnaire from quality metric incorporated
Time Frame: 3 and 6 months evaluation
The physician evaluate ACT change at Taipei Hospital for both group
All participants were assessed for the change of asthma cost using direct and indirect costs from national website
Time Frame: 3 and 6 months
Researchers access the data from National Health Insurance database
All participants were assessed for the Asthma Control Test change using Paediatric Asthma Quality of Life Questionnaire (PAQLQ) questionnaire
Time Frame: 3 and 6 months evaluation
The physician evaluate PASS score change at Taipei Hospital for both group
All participants were assessed for the Peak Expiratory Flow (PEF) change using spirometry
Time Frame: 3 and 6 months
The physician evaluate PEF change at Taipei Hospital for both group
All participants were assessed for the change of Quality of life using MiniPAQLQ
Time Frame: 3 and 6 months evaluation
Physician and researchers evaluate the quality of life using MiniPAQLQ questionnaire
Number of participants both in intervention and control were assessed for the asthma severity change using Global Strategy for Asthma Management and Prevention (GINA) Guideline
Time Frame: 3 and 6 months evaluation
The physician diagnoses asthma change at Taipei Hospital
Secondary Outcomes
- All participants were assessed for their age in the baseline using data of birthday information(Baseline)
- All participants were assessed for the comorbidities with allergic rhinitis using the health data record from Hospital and National Health Insurance(Baseline)
- All participants were assessed for the total serum IgE (kU/I) change from blood assessment(3 and 6 months evaluation)
- All participants were assessed for the comorbidities with atopic dermatitis using the health data record from Hospital and National Health Insurance(Baseline)
- All participants were assessed for the family history of atopic disease using the health data record from Hospital and National Health Insurance(Baseline)
- All participants were assessed for the systemic steroid dosage (prednisolone, mg), using the health data record from Hospital and National Health Insurance(Baseline)
- All participants were assessed for the ICS Dosage (Seretide,mcg), using the health data record from Hospital and National Health Insurance(Baseline)
- All participants were assessed for the Anti-leukotriene (montelukast, tab), using the health data record from Hospital and National Health Insurance(Baseline)